Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Prospect Capital Corporation — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B), while Prospect Capital Corporation trades at $1.61 (market cap $848.77M). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 36.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (26.42%). Which is the better fit depends on your goals.
| GEHC | PSEC | |
|---|---|---|
Market Cap | $30.93B | $848.77M |
Volume | 5,033,451 | 7,084,485 |
Sector | Health | Financials |
52-Week High | $88.16 | $3.05 |
52-Week Low | $59.48 | $1.60 |
Enterprise Value | $39.39B | $2.67B |
Dividend Yield | 0.23% | 26.42% |
Typical Hold Time | — | 78 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
PSEC trades at $1.67, down 3.47% today, with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but negative revenue and net income in 2025. Recent earnings have consistently beaten expectations, though the company faces significant financial volatility with revenue swinging from $635M in 2022 to -$407M in 2025. Dividend distributions continue at $0.04 monthly, providing income appeal despite operational challenges.
The outlook remains cautious with analyst consensus leaning Hold (55%) amid financial instability. Key risks include persistent revenue volatility and negative cash flow. Upside potential exists from consistent earnings beats and deep valuation discounts, but investors should weigh income benefits against fundamental deterioration and bearish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
